Time point | Baseline | During or immediately after the intervention | 6Â months | 12Â months |
---|---|---|---|---|
Enrolment | ||||
âEligibility screening | X | Â | Â | Â |
âInformed consent | X | Â | Â | Â |
âWHO-5 screena | X | Â | Â | Â |
Intervention | ||||
âProblem-solving therapy (1â7 sessions) | Â | X | Â | Â |
Assessments | ||||
âPrimary outcome | ||||
ââPHQ-9 | X | Â | X | X |
âSecondary outcomes | ||||
ââWHO-5 | X | Â | X | X |
ââGAD-7 | X | Â | X | X |
ââPAID-5b | X | Â | X | X |
ââHbA1cb | X | Â | Â | X |
ââTotal cholesterol | X | Â | Â | X |
ââLDL | X | Â | Â | X |
Process outcomes | ||||
âImplementation | ||||
ââFidelity | Â | X | Â | Â |
ââDose | Â | X | Â | Â |
ââReach | Â | X | Â | Â |
âMechanisms of impact | ||||
ââMediators | Â | X | Â | Â |
ââUnintended consequences | Â | X | Â | Â |